Skip to main content

Table 1 Demographic and baseline characteristics

From: Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses

Demographic data

  

Variable

 

Total

  

N=32

Age (years)

 

31-72 (58.0)

Number of regimens of previous chemotherapy

 

1-4 (2)

Sex

Male

20 (62%)

 

Female

12 (38%)

ECOG performance status

0

8 (25%)

 

1

20 (63%)

 

2

4 (13%)

Site of primary cancer

Breast

1 (3%)

 

Colon

6 (19%)

 

Lung

1 (3%)

 

Pancreas

2 (6%)

 

Pleura

1 (3%)

 

Rectum

7 (22%)

 

Soft tissue

2 (6%)

 

Stomach

4 (13%)

 

Other

8 (25%)

  1. Continuous data: Minimum-Maximum (Median).